teriparatide

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Osteoporosis, Postmenopausal

Conditions

Osteoporosis, Postmenopausal

Trial Timeline

Nov 1, 2007 → May 1, 2011

NCT ID

NCT00557310

About teriparatide

teriparatide is a approved stage product being developed by Eli Lilly for Osteoporosis, Postmenopausal. The current trial status is completed. This product is registered under clinical trial identifier NCT00557310. Target conditions include Osteoporosis, Postmenopausal.

What happened to similar drugs?

20 of 20 similar drugs in Osteoporosis, Postmenopausal were approved

Approved (20) Terminated (0) Active (0)

✅raloxifene + PlaceboEli LillyApproved

✅raloxifene + placeboEli LillyApproved

✅MENATETRANONEEisaiApproved

✅Menatetrenone (Vitamin K2)EisaiApproved

✅teriparatideEli LillyApproved

✅Teriparatide + Aspara-CA 600 mg + Alfarol 1.0 µgEli LillyApproved

✅Teriparatide + Strontium ranelateEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01705587	Approved	Completed	Dec 1, 2012	Sep 1, 2016	Osteoporosis
NCT01360424	Approved	Completed	May 1, 2011	Nov 1, 2013	Osteoporosis
NCT00826228	Approved	Completed	Jun 1, 2009	Dec 1, 2012	Osteoporosis
NCT00696644	Pre-clinical	Completed	Jun 1, 2008	Apr 1, 2011	Osteoporosis, Postmenopausal
NCT00535860	Phase 2	Completed	Apr 1, 2008	Mar 1, 2009	Osteoporosis
NCT00577863	Phase 3	Completed	Jan 1, 2008	Dec 1, 2008	Osteoporosis
NCT00557310	Approved	Completed	Nov 1, 2007	May 1, 2011	Osteoporosis, Postmenopausal
NCT00259298	Approved	Completed	Nov 1, 2005	Jul 1, 2009	Osteoporosis
NCT00191867	Phase 2	Completed	Feb 1, 2005	Mar 1, 2006	Osteoporosis
NCT00191321	Phase 3	Completed	Jul 1, 2004	Dec 1, 2005	Osteoporosis
NCT00532207	Phase 3	Completed	Nov 1, 2003	Dec 1, 2004	Osteoporosis, Post-Menopausal
NCT00191893	Phase 3	Completed	Sep 1, 2003	Nov 1, 2006	Osteoporosis
NCT00191802	Phase 3	Completed	Sep 1, 2003	Oct 1, 2005	Osteoporosis
NCT00532545	Approved	Completed	Apr 1, 2003	Apr 1, 2004	Osteoporosis, Post-Menopausal

Competing Products

20 competing products in Osteoporosis, Postmenopausal

See all competitors

Product	Company	Stage	Hype Score
ENZ215 + Prolia	Alkem Laboratories	Phase 3	40
Teriparatide + Alendronate Sodium + Placebo + Placebo	Eli Lilly	Phase 3	40
Teriparatide	Eli Lilly	Phase 3	40
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D Supplement	Eli Lilly	Phase 3	40
raloxifene + Placebo	Eli Lilly	Approved	43
Subcutaneous Teriparatide + Transdermal Teriparatide	Eli Lilly	Phase 2	35
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneous	Eli Lilly	Phase 3	40
raloxifene + placebo	Eli Lilly	Approved	43
Teriparatide + Salmon Calcitonin	Eli Lilly	Phase 3	40
Forteo	Eli Lilly	Pre-clinical	22
arzoxifene + Placebo	Eli Lilly	Phase 2	35
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneous	Eli Lilly	Phase 3	40
CT-P41 + US-licensed Prolia	Celltrion	Phase 3	40
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placebo	Chugai Pharmaceutical	Phase 3	40
Eldecalcitol soft capsules	Chugai Pharmaceutical	Pre-clinical	22
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RIS	Chugai Pharmaceutical	Phase 3	40
Denosumab + Placebo + Alendronate sodium hydrate	Daiichi Sankyo	Phase 3	40
YM529 / ONO-5920	Astellas Pharma	Phase 2/3	38
ONO-5920	Astellas Pharma	Phase 3	40
Minodronic acid hydrate	Astellas Pharma	Phase 3	40